Literature DB >> 6110749

Some factors influencing the metabolism of benzylamine by type A and B monoamine oxidase in rat heart and liver.

D Parkinson, G A Lyles, B J Browne, B A Callingham.   

Abstract

The ability of MAO-A and MAO-B to metabolize benzylamine in vitro has been investigated in mitochondrial preparations from rat liver and heart. Although under normal circumstances benzylamine appeared to be metabolized exclusively by MAO-B in the rat liver, a contribution by both MAO-A and a clorgyline-resistant enzyme component was revealed when the MAO-B activity was much reduced by pretreatment of the mitochondria with appropriate concentrations of deprenyl. These three enzyme activities also contributed to benzylamine deamination in rat heart mitochondria. However, binding studies with [3H]pargyline, which provided an estimate of the respective concentrations of MAO-A and MAO-B active centres in heart mitochondria, indicated a ratio between MAO-A and MAO-B, markedly different from that shown by plots of inhibition of benzylamine metabolism by various concentrations of clorgyline. The interpretation of these clorgyline plots is discussed in terms of the kinetic constants of both MAO-A and MAO-B, and the relative amounts of each enzyme. It is proposed that although the turnover rate constant for benzylamine metabolism by MAO-A is much smaller than that shown by MAO-B, in those tissues containing a large ratio of MAO-A:MAO-B content, the metabolism of benzylamine by MAO-A can be detected.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6110749     DOI: 10.1111/j.2042-7158.1980.tb13088.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

Review 1.  90 years of monoamine oxidase: some progress and some confusion.

Authors:  Keith F Tipton
Journal:  J Neural Transm (Vienna)       Date:  2018-04-10       Impact factor: 3.575

2.  Differential activation of two monoamine oxidase types by oxygen.

Authors:  C Mitra; S R Guha
Journal:  Experientia       Date:  1983-03-15

3.  The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222.

Authors:  M Strolin Benedetti; T Boucher; C J Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-08       Impact factor: 3.000

4.  Inhibition of monoamine oxidase and semicarbazide-sensitive amine oxidase by mexiletine and related compounds.

Authors:  M Eriksson; C J Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-10       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.